BioSpace News Archive

IND for LB-001 in methylmalonic acidemia (MMA)cleared in August 2020, with first patient in Phase 1/2 SUNRISE trial expected to be enrolled in early 2021

First randomized clinical trial demonstrating that CTC count may help personalize treatment choices

BioArctic AB [Nasdaq Stockholm: BIOA B] announced data on the drug candidate BAN2401, which were presented by the company’s partner Eisai at the Clinical Trials on Alzheimer’s Disease conference, November 4-7.

Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization of mammalian and microbial biologics, announces the appointment of Mr. Bin Zhang as Chief Executive Officer.

On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy.

Avellino announced that the company has developed a novel multi-panel RT-PCR-based virus assay, AvellinoCoV2-Respiratory, which has been validated following the U.S. Food and Drug Administration’s Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing CLIA guidelines.

Aptevo Therapeutics Inc., a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ platform, provided an update on its ongoing APVO436 Phase 1 clinical trial.

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a live webinar on Monday, November 16, 2020 at 8:00 a.m. ET highlighting its novel Immunosynthen STING-agonist ADC platform. The presentation will review the therapeutic rationale for the de

Intra-Cellular Therapies today announced its financial results for the third quarter ended September 30, 2020, and provided a corporate update.

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2020. “We are encouraged by our recent Ty